Inovio’s Emergency Funding Move Sends Shares Plunging

Biotechnology firm Inovio Pharmaceuticals has triggered investor alarm with a deeply discounted stock offering that aims to secure crucial funding. The emergency capital raise comes at a substantial cost to existing shareholders, who face significant dilution as the company fights to maintain operations.

Inovio’s latest financial reports reveal a precarious position. During the third quarter, the company consumed $21.2 million in cash while reporting cash reserves of just $50.8 million. This burn rate indicated the company would have faced insolvency by the second quarter of 2026 without immediate intervention.

The newly announced offering involves 13.1 million shares priced at $1.90 each—a substantial discount to previous trading levels. This financing round is expected to generate Read more...